Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Evaluate the Use of the Drug Combination Vorinostat, Niacinamide, and Etoposide in Patients With Lymphoid Malignancies That Have Reoccurred (SAHA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by Columbia University
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Owen A. O'Connor, Columbia University Identifier:
First received: June 3, 2008
Last updated: January 27, 2014
Last verified: January 2014

June 3, 2008
January 27, 2014
June 2008
February 2014   (final data collection date for primary outcome measure)
Determine the maximum tolerated dose (MTD) of all combinations of drugs used in study as specified in protocol; evaluate the safety and toxicity of the studied combinations of vorinostat, niacinamide and etoposide [ Time Frame: continuous ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00691210 on Archive Site
  • Describe the maximum number of cycles received in each part of the study [ Time Frame: continuous ] [ Designated as safety issue: Yes ]
  • Describe the number of dose delays and reductions at the MTD [ Time Frame: continuous ] [ Designated as safety issue: Yes ]
  • Describe the anti-tumor activity [ Time Frame: continuous ] [ Designated as safety issue: Yes ]
  • Evaluate pharmacodynamic markers of target effect in paired tissue biopsies [ Time Frame: continuous ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
A Study to Evaluate the Use of the Drug Combination Vorinostat, Niacinamide, and Etoposide in Patients With Lymphoid Malignancies That Have Reoccurred
Phase I Study of Vorinostat in Combination With Niacinamide, and Etoposide for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies

The purpose of this study is to test the safety of a combination of two anticancer medicines, called vorinostat and etoposide, with a high dose of a vitamin called niacinamide. These medications will be tested at different dose levels. The investigators want to find out what effects, good and/or bad, it has on patients and their recurrent lymphoma. The first two drugs, vorinostat and niacinamide, suppress survival signals that lymphoma cells depend on. The third drug, etoposide can kill sensitive lymphoma cells alone or in combination with other chemotherapy drugs.Vorinostat is an anticancer agent that been approved by the Food and Drug Administration for use in cutaneous Tcell lymphoma. It is being evaluated in this study in combination with other anticancer medicines for use in other types of lymphoma. Vorinostat's use in combination with anticancer regimens is experimental. Niacinamide is a vitamin that is investigational or experimental when given at high doses as an anticancer agent. Niacinamide has not yet been approved by the Food and Drug Administration for use in lymphoma. Etoposide has been approved by the Food and Drug Administration for use in aggressive nonHodgkin's lymphoma. However, the way it will be given in this clinical study is experimental.

Not Provided
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Hodgkin's Disease
  • Non-Hodgkin's Lymphoma
  • Drug: Vorinostat (SAHA) and Niacinamide
    dose escalation scheme
  • Drug: Vorinostat, Niacinamide and Etoposide
    dose escalation scheme
Not Provided
Amengual JE, Clark-Garvey S, Kalac M, Scotto L, Marchi E, Neylon E, Johannet P, Wei Y, Zain J, O'Connor OA. Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. Blood. 2013 Sep 19;122(12):2104-13. doi: 10.1182/blood-2013-02-485441. Epub 2013 Aug 2.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2014
February 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Histologically confirmed relapsed or refractory non-Hodgkin's lymphoma or Hodgkin's Disease (WHO criteria), for which they are unwilling or unable to undergo an autologous stem cell transplant
  2. Must have received first line chemotherapy. No upper limit to number of prior therapies
  3. Evaluable Disease
  4. Age >18 years
  5. ECOG performance status <2
  6. Life expectancy of greater than 3 months
  7. Patients must have adequate organ and marrow function
  8. Adequate Contraception
  9. Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  1. Prior Therapy

    • Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
    • Patient is on any systemic steroids that have not been stabilized to the equivalent of ≤10 mg/day prednisone during the 7 days prior to the start of the study drugs
    • No monoclonal antibody within 3 months without evidence of progression
  2. Patients may not be receiving any other investigational agents
  3. Patients with known central nervous system metastases, including lymphomatous meningitis
  4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat, niacinamide or etoposide
  5. Uncontrolled intercurrent illness
  6. Pregnant women
  7. Nursing women
  8. Patient with a history of a prior malignancy
  9. Patient is known to be Human Immunodeficiency Virus (HIV)-positive
  10. Active Hepatitis A, Hepatitis B, or Hepatitis C infection
  11. Patient has a history of surgery that would interfere with the administration or absorption of the oral study drugs
18 Years and older
United States
Owen A. O'Connor, Columbia University
Columbia University
Merck Sharp & Dohme Corp.
Principal Investigator: Owen A O'Connor, MD, Ph.D. Columbia University
Columbia University
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP